Table of contents
April 2005 Volume 2 No 4
Editorial
Viewpoint
The role of preoperative chemotherapy for esophageal cancer: when is surgery alone feasible?
172International consensus has not yet been reached for the use of preoperative chemotherapy for localized esophageal cancer. Chong and Cunningham give an overview of the latest trials and meta-analyses, discussing possible reasons for discrepant findings, and giving their interpretation of best clinical practice for this disease.
Research Highlights
Predicting recurrence in patients with breast cancer
174Advances in immunotherapy for chronic myeloid leukemia
174Depression and anxiety among breast cancer patients
175Does sunlight reduce the risk of malignant lymphoma?
176Differential gene expression in androgen-independent prostate tumors
176Mechanism of drug resistance in non-small-cell lung cancer
177Long-term follow-up of a smoking cessation intervention
177Practice Points
Re-induction of hormonal sensitivity in hormone-refractory prostate cancer—fact or fiction?
180What is the risk of second malignant neoplasms after childhood cancer?
182Is there a link between macronutrient intake and prostate cancer?
184Can combination salvage therapy for invasive aspergillosis improve patient outcome?
186Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?
188Which should be added to cisplatin for advanced non-small-cell lung cancer—vinorelbine or gemcitabine?
190Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
192Reviews
Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting
196Recent improvements in the development of antiemetics have helped to minimize chemotherapy-induced nausea and vomiting. Oo and Hesketh review the latest clinical trial data and discuss how the introduction of two new antiemetics, palonosetron, a 5-HT3 antagonist, and aprepitant, a NK-1 antagonist, have demonstrated significant advances for patients inadequately controlled with conventional antiemetic regimens.
doi:10.1038/ncponc0132 | Full Text | PDF (106K)
Mechanisms of Disease: inflammatory mediators and cancer prevention
202Discovery of molecular pathways critical to carcinogenesis is revolutionizing the treatment and prevention of cancer. This review discusses recent advances in colorectal cancer chemoprevention and the development of novel anti-inflammatory agents that target signaling pathways important in tumor formation and metastasis, such as those involving cyclooxygenase (COX1 and COX2) and the epidermal growth factor receptor (EGFR).
doi:10.1038/ncponc0140 | Full Text | PDF (337K)
Intensity-modulated radiation therapy for the treatment of pediatric cancer patients
211Intensity-modulated radiation therapy (IMRT) has advantages over standard radiotherapy techniques, but few studies have been performed in pediatric cancer patients, and as a result radiation oncologists have not universally accepted its use. This review discusses the current and future applications of IMRT in pediatric malignancies and its potential pitfalls, and highlights the radiotherapeutic options available for pediatric patients unsuitable for conventional radiotherapy.
doi:10.1038/ncponc0139 | Full Text | PDF (111K)
Case Study
Corrigendum
Corrigendum: Technology Insight: proton beam radiotherapy for treatment in pediatric brain tumors
222doi:10.1038/ncponc0163 | Full Text | PDF (237K)
